Endpoints News 20. Dez. 2025 Nine more MFN deals; Western drugmakers turn to China; Chai Discovery's raise; and more
Endpoints News 19. Dez. 2025 Senators point fingers over who blocked the rare disease voucher reauthorization
Endpoints News 19. Dez. 2025 Altimmune advances in MASH; New China obesity biotech; Ipsen Phase 2 fail
Endpoints News 19. Dez. 2025 Joe Jimenez's Aditum goes to Fosun for major biobuck-loaded collaboration
Endpoints News 18. Dez. 2025 Daiichi and Merck's I-Dxd lung cancer study faces partial hold due to deaths
Endpoints News 18. Dez. 2025 After year of triumph, Insmed stumbles with chronic rhinosinusitis fail, brings in new asset